26,940 Shares in SPDR S&P Biotech ETF $XBI Bought by Marvin & Palmer Associates Inc.

Marvin & Palmer Associates Inc. bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) in the fourth quarter, Holdings Channel reports. The firm bought 26,940 shares of the exchange traded fund’s stock, valued at approximately $3,285,000. SPDR S&P Biotech ETF makes up about 2.3% of Marvin & Palmer Associates Inc.’s investment portfolio, making the stock its 22nd largest position.

A number of other large investors have also bought and sold shares of the company. LPL Financial LLC increased its position in SPDR S&P Biotech ETF by 27.0% in the fourth quarter. LPL Financial LLC now owns 875,547 shares of the exchange traded fund’s stock worth $106,755,000 after buying an additional 185,964 shares during the last quarter. Franklin Resources Inc. increased its position in SPDR S&P Biotech ETF by 3.8% in the fourth quarter. Franklin Resources Inc. now owns 34,139 shares of the exchange traded fund’s stock worth $4,163,000 after buying an additional 1,244 shares during the last quarter. Erste Asset Management GmbH increased its position in SPDR S&P Biotech ETF by 2,213.0% in the fourth quarter. Erste Asset Management GmbH now owns 23,130 shares of the exchange traded fund’s stock worth $2,820,000 after buying an additional 22,130 shares during the last quarter. Manchester Capital Management LLC purchased a new stake in SPDR S&P Biotech ETF in the fourth quarter worth $171,000. Finally, Clearbridge Investments LLC increased its position in SPDR S&P Biotech ETF by 9.8% in the fourth quarter. Clearbridge Investments LLC now owns 395,991 shares of the exchange traded fund’s stock worth $48,283,000 after buying an additional 35,483 shares during the last quarter.

SPDR S&P Biotech ETF Price Performance

NYSEARCA:XBI opened at $131.38 on Wednesday. The business has a fifty day simple moving average of $132.23 and a two-hundred day simple moving average of $126.86. SPDR S&P Biotech ETF has a 1 year low of $80.90 and a 1 year high of $139.19. The company has a market capitalization of $8.38 billion, a P/E ratio of 11.47 and a beta of 0.85.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.